Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (744)	3/27/2008 3:22:54 PM
From: tuck	Read Replies (2) \| Respond to of 804

I think Barr's ANDA will succeed if they succeed in court -- I think Barr has good chances there. Certainly safety and manufacturing is not an issue. The main question is whether or not Celgene's patents hold up, this being a paragraph IV challenge. And those patents are weird, covering the distribution, not the composition of matter or the manufacturing processes. But this is a ways off, isn't it? Celgene sued a little over a year ago, so with the 30 month stay, Barr's version wouldn't be on the market until next fall. I haven't heard of any action since then. Meanwhile, T sales are trending down. Though a generic version would likely reverse that trend and possibly eat into Revlimid sales (and perhaps Velcade sales). You're right to point at this long term. It is one reason I won't chase Celgene. I haven't looked closely at the pipeline in several months; it seemed like the near term stuff was mostly more Imids. I remember hearing their pipe was undervalued a couple of years back, but I don't remember seeing anything exciting on the horizon as a value driver when I looked more recently. Part of the problem is can't see their pdf of their pipeline for some reason, and the html version won't show me the stage of development. Anyone else have this problem? Most of the time, my machine reads pdf files just fine. Cheers, Tuck